CHICAGO, APRIL 5, 2021
— Acadia Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) rejected the application of pimavanserin (Nuplazid) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
The Alzheimer’s Association looks forward to learning full details related to the decision from the FDA and the company in the weeks to come.
Currently, there are no FDA-approved treatments for broad dementia-related psychosis. Dementia-related psychosis, and the other non-cognitive symptoms of Alzheimer’s and other dementia are common for people living with the disease. These symptoms can make living with and providing care for people living with dementia extraordinarily challenging and stressful.
The Alzheimer’s Association remains steadfast in our commitment to accelerating advancements in dementia science and hopeful about the progress in treatments and prevention strategies. Increased federal funding for Alzheimer’s and dementia research, and inventive philanthropic actions such as the Part The Cloud initiative, have opened the door for innovative research that accelerates progress.
The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. For more information, visit www.alz.org or call the 24/7 Helpline at 800.272.3900.